

# Microfluidics for Pharmaceutical Applications: From Nano/Micro Systems Fabrication to Controlled Drug Delivery (Micro and Nano Technologies)

Pages: 463

Publisher: William Andrew; 1 edition (October 12, 2018)

Format: pdf, epub

Language: English

---

**[ DOWNLOAD FULL EBOOK PDF ]**

---

Microfluidics for Pharmaceutical Applications      From Nano/Micro Systems  
Fabrication to Controlled Drug Delivery

First Edition

Hélder A. Santos

Dongfei Liu

Hongbo Zhang

Table of Contents

[Cover image](#)

[Title page](#)

[Copyright](#)

[Contributors](#)

[Preface](#)

[Section 1: Principle of Microfluidics](#)

[Chapter 1: Lab-on-a-chip technology and microfluidics](#)

[Abstract](#)

[Acknowledgements](#)

[1 Introduction](#)

[2 Definition, Main Concepts and Characteristics](#)

[3 Microfluidic Technology for Pharmaceutical Applications](#)

[4 Materials and Processing Techniques](#)

[5 Representative Applications](#)

[6 Summary and Outlook](#)

[Chapter 2: Fluid properties and hydrodynamics of microfluidic systems](#)

[Abstract](#)

[Acknowledgement](#)

[1 Introduction](#)

[2 Fluid Properties](#)

[3 Forces in Microscale Fluid Flows](#)

[4 Effect of Geometry and Scale](#)

[5 Concluding Remarks and Future Outlook](#)

[Chapter 3: Diffusion and mixing in microfluidic devices](#)

[Abstract](#)

[1 Fundamentals of Fluid Flow and Mass Transfer in Microfluidics](#)

[2 Microfluidic Gradient Generator](#)

[3 Microfluidic Mixer](#)

[4 Concluding Remarks](#)

[Chapter 4: Microfluidics for pharmaceutical applications](#)

[Abstract](#)

[1 Introduction](#)

[2 Droplet Formation Using Microfluidic Devices](#)

[3 Applications of Droplet Microfluidics](#)

[4 Multicomponent Multiple Emulsions for Pharmaceutical Applications](#)

[5 Conclusion](#)

[Section 2: Microfluidics for Drug Delivery Applications](#)

## [Chapter 5: Microfabrication and microfluidic devices for drug delivery](#)

### [Abstract](#)

#### [1 Introduction](#)

#### [2 Microfabrication and Pharmaceutical Application of Microfluidic Devices](#)

#### [3 Microfluidic Devices for DDS Applications](#)

#### [4 Conclusion](#)

## [Chapter 6: Lab-on-a-chip preparation routes for organic nanomaterials for drug delivery](#)

### [Abstract](#)

#### [1 Introduction](#)

#### [2 Nanoprecipitation by Hydrodynamic Flow Focusing \(HFF\) for the Production of the Drug Delivery Systems](#)

#### [3 Block-copolymer Assembly in Microfluidic Systems](#)

#### [4 Conclusions](#)

## [Chapter 7: Microfluidic mixing and devices for preparing nanoparticulate drug delivery systems](#)

### [Abstract](#)

### [Acknowledgements](#)

#### [1 Introduction](#)

#### [2 Microfluidics Mixing Enabling Nanoparticles Production](#)

#### [3 Mixing and Devices of Microfluidics](#)

#### [4 Conclusions and Future Prospects](#)

## [Chapter 8: Microfluidic production of inorganic nanomaterials for biomedical applications](#)

### [Abstract](#)

#### [1 Nanomaterials in Biomedical Applications](#)

#### [2 Microfluidic Synthesis of Inorganic Nanomaterials](#)

#### [3 Biomedical Applications of Inorganic nanomaterials Produced by Microfluidics](#)

#### [4 Perspectives and Future Directions](#)

## [Chapter 9: Lab-on-a-chip fabrication of polymeric microparticles for drug encapsulation and controlled release](#)

## Abstract

### 1 Introduction

### 2 Lab-On-A-Chip Fabrication of Microparticles for Controllable Burst Release

### 3 Lab-On-A-Chip Fabrication of Microparticles for Controllable On-Off Release

### 4 Summary

## Chapter 10: Microfluidic technologies for local drug delivery

### Abstract

### 1 Introduction

### 2 Challenges Associated With Local Drug Delivery Through Conventional Particle-Based Methods

### 3 Advantages of Microfluidics for Use in Local Drug Delivery

### 4 Microfluidics for Local Drug Delivery

### 5 Conclusions and Future Perspective

## Chapter 11: Droplet-based microfluidics for cell encapsulation and delivery

### Abstract

### 1 Introduction

### 2 Materials Used for Cell Encapsulation

### 3 Microgels With Tailored Internal Structures

### 4 Applications of Cell Encapsulation in Microgels

### 5 Conclusions and Future Perspectives

## Chapter 12: Antibody discovery using microfluidic systems

### Abstract

### Acknowledgments

### 1 Introduction

### 2 Valve Microfluidics

### 3 Microwells

### 4 Droplet Microfluidics

### 5 High-throughput Sequencing of the Antibody Repertoire

## [6 Concluding Remarks](#)

### [Chapter 13: Single-cell screening using microfluidic systems](#)

#### [Abstract](#)

#### [Abstract](#)

#### [Acknowledgements](#)

#### [1 Overview](#)

#### [2 Three Dominant Microfluidics Types](#)

#### [3 Single-Cell Screening](#)

#### [4 Single-cell Sequencing](#)

#### [5 Concluding Remarks](#)

### [Section 3: Microfluidics for Analysis and Drug Delivery](#)

### [Chapter 14: Lab-on-a-chip techniques for high-throughput proteomics and drug discovery](#)

#### [Abstract](#)

#### [1 Current Challenges in Drug Screening and Proteomics](#)

#### [2 An Overview of Microfluidic Technologies](#)

#### [3 Microfluidics Technologies and Their Drug Candidate Screening Applications](#)

#### [4 Microfluidics Chips for High Resolution Screening](#)

#### [5 Engineering organs-on-a-chips as Replacement of in vitro 2D Cell Culture](#)

#### [6 Whole Organism-On-Chip for Toxicity Assessment](#)

#### [7 Conclusion](#)

### [Section 4: Future Prospective and Commercialization of Microfluidic Techniques](#)

### [Chapter 15: Future of microfluidics in research and in the market](#)

#### [Abstract](#)

#### [1 Introduction—Future of Microfluidics in Nanomedicine](#)

#### [2 Microfluidics and Preparation of Nanomedicines](#)

#### [3 Nanomedicine Manufacturing Scale-Up Using Microfluidics](#)

#### [4 Manufacturing of Microfluidic Devices](#)

[5 Pharmacy-On-Demand and Microfluidics](#)

[6 Wearable Microfluidics Applications](#)

[7 The Way Forward for Microfluidics](#)

[Index](#)

## Copyright

Elsevier

Radarweg 29, PO Box 211, 1000 AE Amsterdam, Netherlands

The Boulevard, Langford Lane, Kidlington, Oxford OX5 1GB, United Kingdom

50 Hampshire Street, 5th Floor, Cambridge, MA 02139, United States

© 2019 Elsevier Inc. All rights reserved.

No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, or any information storage and retrieval system, without permission in writing from the publisher. Details on how to seek permission, further information about the Publisher's permissions policies and our arrangements with organizations such as the Copyright Clearance Center and the Copyright Licensing Agency, can be found at our website: [www.elsevier.com/permissions](http://www.elsevier.com/permissions).

This book and the individual contributions contained in it are protected under copyright by the Publisher (other than as may be noted herein).

## Notices

Knowledge and best practice in this field are constantly changing. As new research and experience broaden our understanding, changes in research methods, professional practices, or medical treatment may become necessary.

Practitioners and researchers must always rely on their own experience and knowledge in evaluating and using any information, methods, compounds, or experiments described herein. In using such information or methods they should be mindful of their own safety and the safety of others, including parties for whom they have a professional responsibility.

To the fullest extent of the law, neither the Publisher nor the authors, contributors, or editors, assume any liability for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products, instructions, or ideas contained in the material herein.

Library of Congress Cataloging-in-Publication Data

A catalog record for this book is available from the Library of Congress

British Library Cataloguing-in-Publication Data

A catalogue record for this book is available from the British Library

ISBN: 978-0-12-812659-2

For information on all Elsevier publications visit our website at  
<https://www.elsevier.com/books-and-journals>

Publisher: Matthew Deans

Acquisition Editor: Simon Holt

Editorial Project Manager: Andrae Akeh,

Production Project Manager: Sruthi Satheesh

Cover Designer: Victoria Pearson

Typeset by SPi Global, India  
Contributors

Sania Arif Department of Industrial Biotechnology, Atta-ur-Rahman School of Applied Biosciences, National University of Science and Technology, Islamabad, Pakistan

Manuel Arruebo

Department of Chemical Engineering, Aragon Institute of Nanoscience (INA), University of Zaragoza, Zaragoza

Networking Research Center on Bioengineering, Biomaterials and Nanomedicine, CIBER-BBN, Madrid, Spain

Adam Bohr Department of Pharmacy, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark

Vanessa F. Cardoso

Center of Physics, University of Minho, Braga

CMEMS-UMinho, University of Minho, DEI, Guimarães, Portugal

Dong Chen Institute of Process Equipment, Zhejiang University, Hangzhou, People's Republic of China

Ran Chen Institute of Process Equipment, Zhejiang University, Hangzhou, People's Republic of China

Zi Chen Thayer School of Engineering, Dartmouth College, Hanover, NH, United States

Liang-Yin Chu School of Chemical Engineering, Sichuan University, Chengdu, People's Republic of China

Stefano Colombo Department of Pharmacy, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark

Jing Fan Department of Mechanical Engineering, The City College of the City University of New York, New York, NY, United States

Antonio Francesko Center of Physics, University of Minho, Braga, Portugal

Shabir Hassan Division of Engineering in Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Cambridge, MA, United States

Yinghe He College of Science and Engineering, James Cook University, Douglas, QLD, Australia

Henrik Jensen Department of Pharmacy, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark

Xiao-Jie Ju School of Chemical Engineering, Sichuan University, Chengdu, People's Republic of China

Nauman Khalid School of Food and Agricultural Sciences, University of Management and Technology, Lahore, Pakistan

Niko Kimura Graduate School of Chemical Sciences and Engineering, Hokkaido University, Kita-ku, Sapporo, Japan

Isao Kobayashi Food Research Institute, NARO, Tsukuba, Japan

Senentxu Lanceros-Méndez

BCMaterials, UPV/EHU Science Park, Leioa

Ikerbasque, Basque Foundation for Science, Bilbao, Spain

Shuaijun Li Department of Mechanical Engineering, The City College of the City University of New York, New York, NY, United States

Dongfei Liu

Drug Research Program, Division of Pharmaceutical Chemistry and Technology, Drug Research Program, Faculty of Pharmacy

Helsinki Institute of Life Science, HiLIFE, University of Helsinki, Helsinki, Finland

Masatoshi Maeki Division of Applied Chemistry, Faculty of Engineering, Hokkaido University, Sapporo, Japan

Linas Mažutis Institute of Biotechnology, Vilnius University, Vilnius, Lithuania

Valdemaras Milkus Institute of Biotechnology, Vilnius University, Vilnius, Lithuania

Juozas Nainys Institute of Biotechnology, Vilnius University, Vilnius, Lithuania

Mitsutoshi Nakajima

Food Research Institute, NARO

Graduate School of Life and Environmental Sciences, University of Tsukuba, Tsukuba, Japan

Alfonso Maria Ponsiglione Department of Chemical, Materials and Production Engineering,  
University of Naples Federico II, Naples, Italy

Maria Russo Department of Chemical, Materials and Production Engineering, University of  
Naples Federico II, Naples, Italy

Hélder A. Santos

Drug Research Program, Division of Pharmaceutical Chemistry and Technology, Drug Research  
Program, Faculty of Pharmacy

Helsinki Institute of Life Science, HiLIFE, University of Helsinki, Helsinki, Finland

Victor Sebastian

Department of Chemical Engineering, Aragon Institute of Nanoscience (INA), University of  
Zaragoza, Zaragoza

Networking Research Center on Bioengineering, Biomaterials and Nanomedicine, CIBER-BBN,  
Madrid, Spain

Karolis Simutis Institute of Biotechnology, Vilnius University, Vilnius, Lithuania

Greta Stonyte Institute of Biotechnology, Vilnius University, Vilnius, Lithuania

Zeyong Sun Institute of Process Equipment, Zhejiang University, Hangzhou, People's Republic  
of China

Manabu Tokeshi Division of Applied Chemistry, Faculty of Engineering, Hokkaido University,  
Sapporo, Japan

Enza Torino Department of Chemical, Materials and Production Engineering, University of  
Naples Federico II, Naples, Italy

David Wibowo Australian Institute for Bioengineering and Nanotechnology, The University of  
Queensland, St Lucia, QLD, Australia

Ziqian Wu Thayer School of Engineering, Dartmouth College, Hanover, NH, United States

Hongbo Zhang

Department of Pharmaceutical Sciences Laboratory

Turku Center for Biotechnology, Åbo Akademi University, Turku, Finland

Yuezhou Zhang Department of Pharmaceutical Sciences Laboratory, Åbo Akademi University,  
Turku, Finland

Yu Shrike Zhang    Division of Engineering in Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Cambridge, MA, United States

Chun-Xia Zhao    Australian Institute for Bioengineering and Nanotechnology, The University of Queensland, St Lucia, QLD, Australia  
Preface

Hélder A. Santos; Dongfei Liu, University of Helsinki, Helsinki, Finland

Hongbo Zhang, Åbo Akademi University, Turku, Finland

Microfluidics is the technology to precisely manipulate nanoliter volume of liquids in designed microchannels. This technology is featured with the ability to use very small quantities of samples and reagents when performing nano-/microfabrication, separation, sorting, detection, and screening with high resolution and sensitivity. This research field merges engineering, physics, and chemistry, and it has broad applications in pharmacy, biology, medicine, and many other fields. Microfluidic devices not only are the science of art but also act as "tiny precision instrument," by creating a magic of mixing.

Microfluidics has revolutionized many fields. It enables super-high-throughput screening and tissue-on-a-chip and lab-on-a-chip (LOC) nano-/microfabrications. The editors of this book were able to collect valuable contributions from top-level scientists, with expertise ranging from microfluidics, pharmaceutical sciences, physics, and biomedical engineering to drug delivery. We want to express our deepest gratitude to all the authors with their enthusiasm in preparing their book chapters, which broadly cover the topics from the fundamental mechanism of flows to the fabrication of drug delivery systems, pharmaceutical analysis, and the commercialization potential of microfluidic technologies.

We collect here detailed frontier advances in microfluidics for pharmaceutical applications. Moreover, we emphasize the concepts rather than technical details. We deliver the message by using case studies, in simple and pedagogical way. And we hope this book can evoke discussions on developing novel drug delivery platforms via microfluidics.

The microfluidic technology has played a fundamental role in pharmaceutical sciences. With droplet microfluidics, we can formulate uniform collection of single and multiple emulsions. After solidification, structured carriers for a variety of pharmaceutical applications can be obtained. All types of drugs, both hydrophobic and hydrophilic, and small molecules, proteins and nucleic acids, can be encapsulated into the engineered carriers by using the corresponding strategies. This technology is also promising in co-loading multiple drugs, which is highly demanded for complex diseases therapy, such as cancer.

Microfluidic nanoprecipitation is a powerful method to produce polymer-based nanoparticles and structured nanovectors. The obtained particles have narrow size distribution, and the encapsulation efficiency is close to 100% regarding the inner ones. Moreover, with a small device, we can fabricate hundreds of grams of nanoparticles per day, which is far beyond the bulk method and meets the industry demand.

Microfluidics can also be used for local drug delivery. The wearable or implantable microfluidic devices are loaded with drugs and can precisely control the release of payloads in a sustained or stimuli-responsive manner.

Apart from the conventional drugs, cell-based therapies are becoming popular. Droplet microfluidics is an ideal technique to encapsulate biosystems, such as yeast cells, mesenchymal

stem cells, hepatocytes, and fibroblasts, to protect and deliver them to the target site.

In addition to cell delivery, droplet microfluidics can also be used for separating cells as single cells in the drops. The microfluidic-based single-cell screening method is a milestone for single-cell analysis that enables the high-throughput screening of 10,000 cells in a few hours. This method has broad applications, including the study of tumor heterogeneity, drug development and screening, and antibody discovery.

LOC enables high-throughput screening of proteomics and drug discovery. By designing the microfluidic modules and geometries, the mixing occurs in drops by chaotic advection, droplets can be split by designing arms, the on-chip dynamic and static incubations can be achieved, reinjection to drops and drops merging are possible, and the drops can be sorted. Therefore, all types of high-throughput screening and reactions can be done in microfluidics.

The organ-on-a-chip strategy offers low-cost and highly biomimetic models for biological analysis. Different organs, including the heart, brain, lung, and intestine, can be mimetic by LOC strategy. By connecting a group of organ-on-a-chip systems, we can have a human-on-a-chip design. Moreover, the pathogen conditions, like cancer, can also be mimetic by tissue-on-a-chip technology.

This book includes some of the most recent breakthrough research in microfluidics for pharmaceutical applications. The book is unique as it combines all the states of art in the field and the applications of the microfluidic technique. In this respect, it is intended as a guide through some innovative contributions from a wide group of outstanding researchers in their respective fields, aiming at an advanced and specialist readership community, and relevant in general to readers in research, academia, or private companies focused on the designing and operation of microfluidic devices and applications. Furthermore, under- and postgraduate students will find in this book a good source of research methods, the underlying principles of how microfluidics work, and the variety of applications they provide. An investor, tech manager, or business man will find an area to invest in and the viability of a certain application or device for mass production and commercialization from this book. Overall, the contents of this book provide an indispensable support to guide the readers in the field of microfluidics for pharmaceutical applications, encompassing a wide range of disciplines, including microfluidics, chemistry, physics, materials science and engineering, biology, pharmaceuticals, and medicine.

The Editors

Section 1

Principle of Microfluidics

Chapter 1

Lab-on-a-chip technology and microfluidics

Antonio Francesko<sup>\*,a</sup>; Vanessa F. Cardoso<sup>\*,†,a</sup>; Senentxu Lanceros-Méndez<sup>‡,§</sup>; \* Center of Physics, University of Minho, Braga, Portugal

† CMEMS-UMinho, University of Minho, DEI, Guimarães, Portugal

‡ BCMaterials, UPV/EHU Science Park, Leioa, Spain

§ Ikerbasque, Basque Foundation for Science, Bilbao, Spain

a These authors equally contributed to this work.

Abstract

This chapter presents an overview of the main topics related to microfluidics for pharmaceutical

applications. It begins with a general introduction on lab-on-a-chip technology and microfluidics, in which the main definitions, concepts, and characteristics are presented. Further, the main materials and processing techniques used for the development of microfluidic systems are introduced. Finally, the most representative applications are discussed. Applications are focusing on the areas of drug development, drug delivery and diagnosis, cell-based devices, and organs-on-a-chip devices, the latest step toward whole-body models. Thus, a complete overview in the area is provided, followed by a summary and outlook on open questions and future trends.

### Keywords

Microfluidics; Pharmaceutical applications; Lab-on-a-chip; Organ-on-a-chip; Drug testing

Chapter Outline	1. <a href="#">Introduction</a>	2. <a href="#">Definition, Main Concepts and Characteristics</a>		
3. <a href="#">Microfluidic Technology for Pharmaceutical Applications</a>	4. <a href="#">Materials and Processing Techniques</a>			
	4.1. <a href="#">Silicon and Glass</a>	4.2. <a href="#">Polymers</a>	4.3. <a href="#">Paper</a>	5.
<a href="#">Representative Applications</a>		5.1. <a href="#">Microfluidic Technology for Drug Development, Drug Delivery and Diagnostics</a>		
<a href="#">Whole Body Models</a>	5.2. <a href="#">Cell-Based Devices</a>	5.3. <a href="#">Organs-On-A-Chip, A Step Toward</a>		
<a href="#">Further Reading</a>	6. <a href="#">Summary and Outlook</a>	<a href="#">Acknowledgements</a>	<a href="#">References</a>	
		Acknowledgements		

The authors thank the Fundação para a Ciência e Tecnologia (FCT) for the financial support under the framework of the Strategic Funding UID/FIS/04650/2013, project PTDC/EEI-SII/5582/2014, and project UID/EEA/04436/2013 by FEDER funds through the COMPETE 2020—Programa Operacional Competitividade e Internacionalização (POCI) with the reference project POCI-01-0145-FEDER-006941. Funds provided by FCT in the framework of EuroNanoMed 2016 call, project LungChek (ENMed/0049/2016), are also gratefully acknowledged. VFC and AF also thank the FCT for the postdoctoral grants SFRH/BPD/98109/2013 and SFRH/BPD/104204/2014, respectively. Finally, the authors acknowledge funding by the Spanish Ministry of Economy and Competitiveness (MINECO) through the project MAT2016-76039-C4-3-R (AEI/FEDER, UE) and from the Basque Government Industry Department under the ELKARTEK program.

“Everything in excess is opposed to nature”

Hippocrates (460–377 BC)

## 1 Introduction

Since the introduction of a miniaturized gas chromatography analyzer on a silicon wafer in the 1970s by Terry et al. [1] and most prominently since the conceptual work on a miniaturized total chemical analysis systems by Manz et al. in 1990 [2], the field of micro total analysis systems ( $\mu$ TAS) or lab-on-a-chip (LOC) technology has been under intensive development in many biotechnological areas spanning from basic theoretical models and academic proof-of-concept studies to commercial applications. LOC are ideally described as miniature versions of their macroscale counterparts and therefore usually integrate all the component units of a complete laboratory assay [3]. The term microfluidic is generally used to describe the precise control and manipulation of small volume of fluids on a micrometer scale, which is the basis of LOC systems. The attractiveness of such miniaturized systems can be attributed in large part to its size effect, which allows portability, low consumption of sample/reagents and power, and short assay time. Further, it is associated to some unique physical phenomena that emerge at such scale and bring numerous benefits in pharmaceutical applications from the early drug discovery and screening stage to the final targeted and controlled delivery stage, as will be addressed later [4]. The high interdisciplinarity of this technology has received inputs from a large spectra of researchers from different areas of expertise in order to develop and apply microfluidics in a wide range of (bio)technological applications, such as clinical diagnostic [5], proteomics [6], cell and tissue

engineering [7], pharmacology [8], and environmental monitoring [9], among others [10,11]. The value of this technology is demonstrated by the growing number and improved quality of published papers [12]. According to the ISI Web of Science, about 45,000 of documents related to microfluidics have been published since 2000 being almost 10% related to pharmaceutical applications (Fig. 1.1).

Fig. 1.1 Published items related to “microfluidics” by year since 2000. Data from ISI Web of Science.

This strong growth over the years along with the potential to produce revolutionary and practical miniaturized devices has led to the emergence of a number of companies dedicated to microfluidics and LOC for different application areas, being approximately 274 worldwide in February 2016 [13]. Some examples are Abaxis (diagnostics), Advanced Liquid Logic (research instruments), Biosite (diagnostics), Chiral Photonics (packaging, prototyping, and manufacturing), Aixtek (consulting), FlowJEM (prototyping), Microfluidic Imaging (imaging), Cepheid (diagnostics), Cytonome (therapeutics), Micronics (custom development, manufacturing, and research instruments), Microflow Laboratory (consulting and prototyping), Medtronic (medical devices), Luna Innovations (contract R&D), ALine Inc. (development and components), and i-STAT (diagnostics). This technological boom led MIT Technology Review to nominate microfluidics as one of the 10 technologies that will change the world, with particular relevance in the life science area [14].

The present chapter provides a general description of the essential components and properties of LOC systems, including concepts of materials and fabrication techniques. Further, their applications in relevant biotechnological fields are presented and discussed. In particular, the applicability and advantages of microfluidic technologies in the pharmacological area will be highlighted. The main objective is to provide an overview to scientists and engineers on the possibilities and potential offered by microfluidic technologies to develop innovative and improved products for drug discovery and development.

2 Definition, Main Concepts and Characteristics

As briefly described above, LOC systems are based on a broader technology called microfluidics, the science and engineering of manipulating and processing small volumes of fluids (typically from 100 nL to 10  $\mu$ L of samples and reagents) in microchannels that have at least one dimension (e.g., channel width, depth, or diameter) with length scale from 10 to 100 of micrometers. LOC are often described as miniaturized versions of their macroscale counterparts. This means that successful operation of technically complex assays on chip is designed to include all or most of the components and stages of a complete laboratory procedure in an integrated, automated, and small platform (Fig. 1.2) [5]. These stages can include sampling, sample pretreatment, chemical reactions, product separation and isolation, detection system, and data analysis [15]. Therefore, different kinds of components such as filters, pumps, valves, actuators, heaters, motors, and other functional units have been miniaturized. Likewise, detection systems, such as sensors and detectors, including optical, magnetic, and electric detection, and all the associated electronics have been developed, integrated, and successfully applied in LOC [16].

Fig. 1.2 General components of a LOC.

The strong decrease in the length scale gives rise to unique, important, and sometimes nonintuitive phenomena at the microscale that are not present at the macroscopic scale and are essential for many biotechnological applications. In this context, fluid flow can be typically characterized by two regimes: laminar or turbulent, which is defined by the relative contribution of inertial and viscous forces on a fluid flowing in a channel. It is usually described by the Reynolds number ( $Re$ ), a dimensionless parameter defined by the density and viscosity of the fluid, plus the

average velocity of the fluid flow and the characteristic length scale (e.g., diameter of the channel) [14,17]. The transition between laminar and turbulent flow typically occurs above a Re of 2000 in internal flows [14]. Inertial forces dominate at larger Re, while viscous forces govern at low Re. Therefore, reducing the characteristic length scale has the same effect on the fluid behavior in terms of Re as increasing the viscosity of the solution. This means that in microfluidic systems, flows are well below Re of 100 or even below unity, and so, the flow is truly laminar, dominated by viscous forces. Thus, the fluid velocity is invariant with time at all locations when the boundary conditions are constant [17]. As a consequence, fluid streams flow parallel to each other, and mixture between them occurs just through convective and molecular diffusion. This enables the design of separation and detection devices on laminar fluid diffusion interfaces [18–20]. However, this fact has also important implications in many applications requiring the mixture of fluids, especially when low diffusion coefficients are present. Nevertheless, to overcome this limitation, powerful passive and active mixers have been developed and successfully integrated in microfluidic systems [21–23]. Another critical issue to consider in microfluidic system is the fluid transport system, that is, sample introduction and/or extraction. In fact, flow rates ranging from hundreds of microliter per minute for high-volume throughput to picoliter per minute for applications requiring micron- to submicron-sized channel must be obtained using precise fluid drivers [24,25]. To achieve such requirements, two main methods have been employed. Microfluidic channels made of materials that are charged under experimental conditions are used to induce the well-known phenomenon of electroosmotic flow (EOF). In this case, a blunt fluid flow profile is obtained (Fig. 1.3A), being however susceptible to variation of channel wall coating and fluid composition, limiting its use as generic pumping system [26,27]. In turn, pressure-driven flow by using mechanical positive displacement pumping shows the advantage of very little compliance, which allows controlling the exact volume of pumped fluid and knowing the exact location of the fluid meniscus within the microchannel. A particularity of this system is that the fluid flow exhibits a nonuniform velocity profile, which is usually pseudoparabolic, that is, maximum at the center of the microchannel and decreasing to zero velocity immediately near to the channel walls (Fig. 1.3B) [28,29]. Such systems are mechanically complex and hard to miniaturize, and very low flow rates are generally difficult to obtain. Nevertheless, these fluidic transport systems have demonstrated their suitability in many biotechnological applications, being the system of election by most of the researcher in this area [14].

Fig. 1.3 Schematic representation of (A) electroosmotic flow and (B) pressure-driven flow.

In view of the above and from a technological point of view, it is possible to claim that LOC technology offers many unique benefits when compared with larger-scale conventional systems that include the following: (i) miniaturized devices, allowing portability, in situ measurements, and development of point-of-care systems; (ii) minute consumption of fluids, ideal for handling costly and difficult-to-obtain samples and reagents; (iii) reduced production of waste, making them environmental friendly; (iv) reduced energy consumption; (v) ability to perform high-throughput analysis by processing several assays in parallel; (vi) quick reaction and fast analysis, allowing the results to be obtained within seconds or minutes, instead of hours or days; (vii) improved sensitivity/precision; (viii) versatile and controllable processing of the microfluidic systems at dimensions from micrometers to nanometers; and (ix) widely applicable building materials including plastic to produce microfluidic systems at very low unit cost, allowing them to be disposable and avoiding any type of cross contamination [6,21,22].

Technology for Pharmaceutical Applications

From the pharmaceutical application point of view, microfluidic systems offer a better representation of the realistic physiological and pathological conditions of complex systems for both fundamental research and drug development comparatively with conventional macroscale in vitro assays that continue to give misleading and nonpredictive data for in vivo response [30,31].

In fact, microfluidic systems allow to model biological environments and physically mimic the complex cell-cell and cell-microenvironment interactions found in biological tissue and organs (such as the liver, lung, gastrointestinal tract, kidney, and heart), usually referred as “organ-on-a-chip” [32–34], or at least some of the physiologically relevant processes related to the so-called adsorption, distribution, metabolism, and elimination (ADME) processes in the body, which have an important role in expediting early stages of drug discovery and help to bypass animal testing [35,36]. This is because microfluidic systems can provide a precise control of the fluidic microenvironment, which is particularly relevant and representative, as many important biological processes in cells and other biological entities take place and have sizes at the micrometer scale, matching microfluidic channel dimensions (Fig. 1.4).

Fig. 1.4 LOC technologies as tools at molecular and cellular scale [30].

Fluid flows are an important part of both healthy and pathological conditions, including not only the more obvious flow of blood and lymph in the circulatory system but also the interstitial flow of blood in nearly all soft tissues. The accurate manipulation of fluid flows in microfluidic systems, with high surface-area-to-volume (SAV) ratio, allows to replicate blood circulation in three-dimensional (3-D) microenvironments, with microvascular perfusion and diffusion between mimicked microvessels and 3-D cell culture providing a continuous supply of nutrients and oxygen, which is closer to what cells encounter in real tissues or organs, alleviating the translational barrier to in vivo expectations [37,38]. Moreover, a uniform thermal field and precise temperature control are reached due to the excellent heat transfer properties [39,40]. However, high SAV is also usually associated with high protein adsorption depending mostly on the wetting properties of the microfluidic system (that can be physically important to the cultured cells). To overcome these limitations, specific surface modifications of the microchannels by plasma treatment or coating with specific chemical compounds have been adopted [41,42]. Therefore, key aspects of the biological setting include both micrometer structures and properties, as well as controlled fluid flow over the spatiotemporal environment, which can be simulated in microfluidic systems. A high degree of architectures and biocompatible materials, well-developed and well-characterized microfabrication technologies, also provide researchers with a large toolbox to produce specific and tailored designs in a reliable and reproducible manner. Another aspect is the fact that real-time monitoring of cells or tissue-specific response using standard microscopy techniques are also possible since microfluidic systems made of transparent materials, such as glass or polymers, can be designed to fit on top of a standard microscope slide [15,17,30,39]. Finally, microfluidic system allows to significantly save cell and drug sample volumes from 10- to 1000-fold less than the conventional counterparts, facilitating systematic high-volume testing in various stages of the drug discovery process that could be prohibitively expensive otherwise since the quantities of tested drugs or cells are normally very limited in pharmaceutical research and development [37].

Therefore, with mimicked close-to-in vivo microenvironments and organ-on-a-chip designs, 3-D microfluidic cell culture systems will increase the in vitro drug screening accuracy that in turn would reduce failing rate through clinical trials in the near future and facilitate the development of safer and more effective drugs, namely, in terms of controlled and targeted delivery, at a reduced cost [37]. The next step is to connect various organs-on-a-chip devices in order to create “body-on-a-chip” that will allow not only to study the effects of drugs in individual organs but also to simulate the interactions between various organs, providing a more complete and comprehensive analysis that would ultimately revolutionize how drugs are developed [32,43,44]. Current works on organs-on-a-chip involve intestine-liver [45], liver-kidney [46], and intestine-liver-skin-kidney cocultures [47] and neurosphere and liver spheroid cocultures [48], among others. Details of different types of organ-on-a-chip, with attention brought to their design, materials, objectives, and results, are further discussed in Section 5.3 or can be found in excellent reviews related to this matter [32,35,43,44]. In addition, the unique advantages, compactness, and

controllability of LOC have allowed the development of implantable smart microfluidic drug delivery systems consisting of a number of biocompatible microscale components that can regulate and monitor the delivery of the right amount of drug into a specific target site. Such microdevices have been developed for the treatment of cancer, cardiovascular disorder, eye and brain diseases, stress, and diabetes [49–51].

Important from a technological point of view, microfluidic systems are applied not only for assay development and disease treatment/diagnosis but also for templating nano- and microparticles during their fabrication for various pharmaceutical applications and, in particular, for drug delivery purposes. Droplet microfluidics with precisely controlled production of droplets to be used as templates for reproducible and scalable particle fabrication allows significant improvements in tuning sizes (with minimal deviation from mean dispersity values), shapes, and morphologies of the materials when compared with traditional bulk techniques. Typically, particle fabrication comprises three consecutive steps: (i) formation of droplets in microfluidic generators; (ii) shaping of these droplets in specially designed microchannels; and (iii) solidification by chemical, photochemical, or physical methods to form final particulate emulsions [52]. Passive or active droplet generation methods are adopted [53] according to the desired design and final application, for the production of spherical and nonspherical particles, microcapsules, and vesicles of both organic and inorganic origin, based on single and double multiemulsion templates. The latter are expectedly more challenging to manufacture, due to the requirement of using two-phase systems and their precise control to achieve complex shapes, such as the core-shell design [54]. On-chip fabrications of drug delivery systems have been recently reported, achieving complexity in drug carriers coupled to their precise size and composition that contribute to better prediction and tunability in the drug release profiles [55]. Efforts for advancing manufacturing and control of drug delivery particulate-based systems are excellently reviewed in Riahi et al. [56].

4

Materials and Processing Techniques

The materials that have been employed for the fabrication of microfluidic systems range from silicon, glass, and ceramics to polymer-based materials that include elastomers, thermosets, thermoplastics, and more recently paper. Depending on the application, required function, and degree of integration, special attention should be paid on choosing the correct material for the fabrication of the microfluidic system as it determines both the inherent properties of the device and the possible fabrication technologies that can be used [57]. Characteristics such as flexibility, air permeability, electric conductivity, solvent compatibility, optical transparency, and biocompatibility may be important when selecting a material [58]. Another important factor is the cost that must be minimized in order to fabricate cost-effective products and single-use disposable devices to avoid cross contamination between essays.

#### 4.1 Silicon and Glass

Silicon and glass are typically processed by well-known fabrication methods from the semiconductor industry (Figs. 1.5 and 1.6) such as bulk micromachining using wet and dry etching, although silicon structures can also be fabricated by surface micromachining [59]. Bulk micromachining produces structures within the substrate, that is, substrate is selectively etched, using photolithography to transfer a pattern from a mask to the surface. In turn, surface micromachining allows developing structures on the top of the substrate, which means that thin layers of silicon are subsequently deposited using chemical deposition methods. Silicon is transparent to infrared light, but not in the visible spectral range, making fluorescent detection or fluid imaging challenging.

Fig. 1.5 PDMS microfluidic chip for cancer cell separator using size-dependent filtration. The PDMS microchannel was produced by replica molding using an SU-8 master mold fabricated by photolithography. (A) Concepts of the microfluidic chip for filtering ultralow concentrated cancer cells in patient's peritoneal washes. (B) Fabrication process of the microfluidic chip. SU-8 sheet and two-step exposure were used to make a mold of the chip. The two-step exposure was

performed to fabricate a precise uneven PDMS channel for cell filtration. (C) Photograph of fabricated microfluidic chip. The main channel and shallow channels had heights of 100 and 8  $\mu\text{m}$ , respectively. Bar is 10 mm. Adapted from T. Masuda, M. Niimi, H. Nakanishi, Y. Yamanishi, F. Arai, Cancer cell separator using size-dependent filtration in microfluidic chip. *Sensors Actuators B Chem.* 185 (2013) 245–251.

Fig. 1.6 Three-dimensional paper-based microfluidic device that enables vertical flow multistep assays for the detection of C-reactive protein based on programmed reagent loading. (A) Schematic representation of the paper-based device. The device consists of two layers. The priming and reagent solutions for colorimetric protein and glucose bioassays were preloaded to each reservoir of the top layer. (Step 1) The test solutions were loaded to each injection zone of the bottom layer. (Step 2) The chemical reactions in folded paper-based 3-D microfluidic device through tip-pinch manipulation of the thumb and index fingers. (Step 3) Air dry and image readout after unfolding. (B) Paper-based 3-D microfluidic devices (i) before and (ii) after wax impregnating. Hydrophobic patterns could be clearly observed in the back view after wax impregnating. Scale bar = 10 mm. (C) Colorimetric bioassays and intensity analyses of glucose concentrations with three image readout instruments. Calibration curves for glucose concentrations of 0–50 mM were  $R^2 = 0.9781$  for the scanner, 0.9686 for the microscope, and 0.9658 for the smartphone.

Adapted from S. Choi, S.K. Kim, G.J. Lee, H.K. Park, Paper-based 3D microfluidic device for multiple bioassays. *Sensors Actuators B Chem.* 219 (2015) 245–250.

On the other hand, glass is optically transparent and shows low-background fluorescent. Further, glass modification chemistries are silanol-based, such as for silicon. Favorable properties of silicon and glass come from their thermostability and solvent compatibility. Therefore, nonspecific adsorption can be reduced or cell growth improved through chemical modification of the surface. Nevertheless, the hardness of silicon and glass, the higher cost and time of fabrication, and the difficulty to seal the microfluidic structure and to fabricate and integrate functional units, together with the nongas permeability, have prevented their use in many microfluidic applications and motivate the use and development of other materials that can be easily fabricated and are compatible with a broader range of biological applications [60].

#### 4.2 Polymers

Polymer-based microfluidic systems appear as an interesting alternative, in particular for being relatively inexpensive, suitable for mass production processes, and adaptable through formulation changes and chemical modification [61,62]. An additional benefit is the wide range of available polymers that offer a large flexibility in the selection of material with specific properties. According to their physical properties, polymers can be classified into thermosets, elastomers, and thermoplastics. Thermosets such as SU-8 are normally stable even at high temperature, resistant to most solvents, and highly biocompatible and usually show proper transparency and mechanical properties. SU-8 allows the fabrication of high-aspect ratio and free-standing microstructures using soft lithography [63,64]. When properly heated and exposed to specific UV light using high-resolution photomasks with an inverse pattern (as the resist is negative), the parts exposed become cross-linked, while the remainder is soluble and removed during development process. Therefore, SU-8 has been often used as structural material for the fabrication of functional units (e.g., microelectromechanical systems) and often as permanent building template for microfluidic systems based on poly(dimethylsiloxane) (PDMS), the most popular elastomer in microfluidics (Fig. 1.5). In the latter case, during the process, generally called replica molding, PDMS liquid prepolymer is cast on photoresist templates, thermally cured at mild temperature (40–70°C) and peeled off easily due to its low surface tension [65]. To enclose the obtained open microfluidic channels, PDMS can be bonded reversibly to PDMS, glass, or other substrates by simply making contact or irreversibly by using oxygen plasma treatment or a thin mildly cured layer of PDMS as glue.

PDMS shows very interesting properties for the fabrication of functional units (e.g., valves and

pumps) or/and for the fabrication of PDMS microfluidic systems for biotechnological applications (e.g., for long-term cell culture, cell screening, and biochemical assays in sealed microchannels) that include high biocompatibility, porous matrix allowing permeation of gases, high elasticity and reasonable cost, rapid fabrication, and ease of implementation [66,67]. However, the nonspecificity and permeability by hydrophobic molecules into the channel walls due to the hydrophobicity of the PDMS surface along with the water evaporation through channel walls can cause a change in the concentration and composition of the fluid. Several strategies such as chemical surface modification along with using continuous flow can often be addressed to overcome these issues [68]. Regarding thermoplastics, because of their wide use in the industry, their processing by thermomolding is well known. In this case, a large number of structures can be produced at high rate and low cost using metal or silicon templates and high temperatures. However, the fabrication of this kind of templates is time-consuming and expensive and therefore is not widely used for prototypes, being excellent for commercial production [57]. Typical approaches for sealing open microchannels include thermobonding and glue-assisted bonding [69]. Moreover, surface grafting or dynamic coating can be used to modify the surface of thermoplastics, and electrodes are easily integrated [70]. Thermoplastics show the interesting ability of being reshaped multiple times by reheating, which is appropriate for molding and bonding. Poly(methyl methacrylate) (PMMA), polystyrene (PS), polyethylene terephthalate (PET), and polyvinyl chloride (PVC) are typical thermoplastics used for the fabrication of microfluidic systems [57]. Although thermoplastics show slightly better solvent compatibility than PDMS, they are barely permeable to gases, and their rigidity makes the fabrication of functional units difficult. In turn, although their melting temperatures are high (i.e., over 280°C), perfluorinated polymers, such as perfluoroalkoxy (commonly known as Teflon PFA) and fluorinated ethylene propylene (Teflon FEP), show good gas permeability, enough softness to fabricate functional units, excellent inertness to chemicals and solvents, antifouling, low nonspecific protein adsorption compared with PDMS, cellular compatibility over 5 days, and good optical transparency [58].

4.3

Paper

Paper is a cellulose-based material recently introduced as a promising substrate for the development of flexible, disposable, biocompatible, and low-cost microfluidic systems. In addition to generating flow to transport aqueous liquids due to its porosity and hydrophilicity and allowing further filtering and separation, paper can be chemically modified and conjugated with many biomolecules, including peptides and nucleotides [58]. Based on these properties, paper-based microfluidic systems have been mainly developed for diagnosis purposes since the white background provides a contrast for color-based detection techniques (Fig. 1.6).

Based on the results obtained in this field, it is believed that paper could provide an advantageous platform for accomplishing in vitro precompound screening steps, offering a solution to many economical obstacles inherent in the pharmaceutical industry [71]. Therefore, it is shown that a large set of materials and processing technologies are currently available for microfluidic system development, and new ones are emerging at a rapid rate. Nevertheless, although different materials can be modified or combined to fabricate powerful devices for specific applications, current trends demonstrate that for laboratory research, the proper selection of materials typically implies ease in prototyping and high performance of the system, while in the industry, the major concerns rely on the cost of production and the reliability in use [57].

5

Representative Applications

During the last decade, a significant amount of studies has emerged taking advantage of the characteristics of microfluidic systems for simple sample handling, reagent mixing, separation, and detection of the complex biological environments. Along with this, recent improvements in fabrication techniques allow the manipulation of difficult samples and reagents, while still reducing overall costs. Important for pharmaceutical testing, modern microfluidic devices require between 0.1 and 10  $\mu\text{L}$  of sample, significantly decreasing sample and waste volumes. Initial

attempts are already carried out to industrialize the fabrication and design of parallel flow of several fluids, meaning multiple samples scanning on a single and portable device. In addition, recent technological advances in material science led to even more obvious reasons for pursuing microfluidics for pharmaceutical applications. Indeed, fabrication of microfluidic systems on plastic or paper materials allows for mass production at low costs, and these devices can even be disposable. Meanwhile, the investigation toward optimizing designs for high-throughput screening multiple assays will considerably reduce time and human effort compared with standard *in vitro* and *in vivo* analysis. Meanwhile, additional investigations are still necessary for confirming the credibility of highly complex LOC capable of sampling, processing, separation, detection, and waste handling on a single chip. Such fast and continuous progress makes microfluidics the technology of choice for future drug discovery/development; pharmacokinetic evaluations and toxicity screenings; drug delivery; diagnostics; and, lately, developing of *in vitro* 3-D and whole-body models for analysis. To this end, this section is aimed to present some of the most representative examples of microfluidic systems for pharmaceutical investigations, from commercialized simple LOC devices to novel, highly complex miniaturized designs.

#### 5.1 Microfluidic Technology for Drug Development, Drug Delivery and Diagnostics 5.1.1 Protein expression and enzyme activity/kinetics

Gaining deeper insights of relevant targets for drugs, such as membrane proteins and enzymes, is of paramount importance for advances in pharmaceutical concepts, which will also lead to better understanding the effects of drugs on biological systems and to profile the effects on the metabolic pathway level [72]. Thus, the development of microfluidic devices for cell-free screening is of particular importance in drug discovery for a clear *in vitro* view on drug-target effects. One such study aims to significantly reduce consumption of reagents in drug discovery by the development of a strategy for parallel high-throughput modules for cell-free expression of functional cell proteins [73]. The disposable device is compatible with 96-well microplate readouts and couples a reaction microchamber with adjacent loading ports and the feeding chamber. The tested membrane-associated proteins were bacteriorhodopsin and apolipoprotein A, both expressed in a single reaction, whereas soluble luciferase and  $\beta$ -lactamase were also cosynthesized.

Related to advances in drug-target research and early-stage toxicity screens, the information of kinetic data on the reaction of enzymes with small molecules are gaining significance for drug discovery and development [74]. Here, the additional challenge that the developed microfluidic platforms has to meet is the rapid (within minutes) determination of enzyme activity and automated measuring [75]. To do so, enzymes are typically immobilized on solid supports in microchannels that are subjected to a continuous flow of reagents. The same design is also employed for the determination of enzyme inhibition in microchannels, this time from the generated fluorescence data. Of especial relevance is that the results in a microfluidic approach are obtained after just 2 min, compared with 15 min necessary for the same data in the standard plate approach [76].

#### 5.1.2 Diagnostics

Although of secondary interest for the pharmaceutical industry, there is a strong focus in developing microfluidic systems for early diagnosis, particularly relevant for difficult-to-treat diseases and conditions, for example, malignant tumors or nosocomial infections. Together with their simplicity and improved diagnostic speed compared with time-consuming off-site laboratory tests, microfluidic devices are being developed aiming at better sensitivity and portability. An example is the development of compact disk-based microfluidic systems able to automatize biochemical assays and immunoassays that are eliminating human errors and allow minute reagent consumption during detection [77]. The type of samples for testing and their collection are not affected by the device design due to the fact that the sample collection remains external, as in the case of any other testing. Examples of the device fabrication range from simple microfluidic immunoassays for rapid saliva-based clinical diagnostics [78] to simultaneous multidetection of

hepatitis B, hepatitis C, and HIV biomarkers in blood serum [79]. In line with the latter, research focus is directed to develop point-of-care testing devices for infectious diseases (in particular HIV), of paramount interest for public health (Fig. 1.7) [80,81].

Fig. 1.7 Imaging platform for detection captured cells with a disposable microfluidic device. (A) When light is incident on the captured cells, cells diffract and transmit light. Shadows of the captured lymphocytes generated by diffraction can be imaged by the device in 1 s. Image is obtained with the lensless imaging platform. (B) Photograph of the microfluidic chip and the imaging platform. The entire microfluidic device can be imaged without alignment by simply placing the microfluidic channel on the sensor. (C) Image taken with the imaging platform and the shadow image of the cell in the microfluidic channel is shown. The image is obtained by diffraction. Scale bar = 100  $\mu\text{m}$ . Adapted from S. Moon, H.O. Keles, A. Ozcan, A. Khademhosseini, E. Hæggstrom, D. Kuritzkes, U. Demirci, Integrating microfluidics and lensless imaging for point-of-care testing. *Biosens. Bioelectron.* 24 (2009) 3208–3214.

Regardless of the sample, multimodal detection is of specific interest for developing competitive immunoassays and simultaneous detection of biomarkers with preference of measuring their fluorescence signals. Nevertheless, label-free immunoassays are also being conducted in microfluidic systems thanks to the coupling with robust and sensitive detection methods, such as surface plasmon resonance [82] and imaging ellipsometry [83], generating consistent results with widely accepted ELISA tools. One of the newest paradigms in cancer diagnosis and treatment are exosomes, released from both normal and cancer cells, however with a different footprint and role in remote cell-to-cell communication and signaling [84]. These large extracellular vesicles could serve as carriers for bioactive proteins and different RNA molecules, which means involvement in tumor progression, metastasis, and even drug-resistance mechanisms [85,86]. In this context, an initial tumor could be detected by identifying exposing exosomes in related body fluids (e.g., sputum, blood, and serum), released at a very early step in tumor progression. Logically, they became not only targets for new drug discovery and development but also biomarkers for the diagnosis of cancer or even seen as transport vehicles for drug delivery [87,88]. Thus, exosomes are being targeted by future microfluidic systems that should feature design and dimensions accommodated to the size of these vehicles. The use up to date is still in its infancy and concerns replacement of processes of ultrafiltration and/or ultracentrifugation for the isolation of exosomes from cell culture supernatants. The traditional centrifugation protocols are limited to isolation based on the size of bioentities and cannot distinguish between different exosomes, those from healthy cells and those from tumor. By using microfluidic channels with especial patterns, similar to that used to isolate rare circulating tumor cells from blood [89] and similar dimensions to small vesicles, it is anticipated that such shortcoming might be resolved that will allow improved handling, analysis, and manipulation of exosomes. Overall, a broader use of microfluidic platforms is yet to be established in diagnostics, as both reliable point-of-care home/clinical devices and separation/purification tools.

### 5.1.3 Microfluidic high-throughput screening

Systematic screens and large data processing became an integral part of pharmaceutical research that facilitates the evaluation of complex reactions, interactions, and systems. Systematic screens are useful to resolve massive data for chemical [90], biochemical [91], and cell-based assays [92]. Since global screens in pharmacy lead to improved reliability of the developed treatments, today's existing libraries are counting up to tens of thousands of elements. Microfluidics-based systematic screens are likely to be more frequently used in the near future. First progress was achieved by Caliper Life Sciences with their generic platform employed for various types of high-throughput screening (HTS) applications [93]. Its primary use is carrying out enzymatic assays on a glass microchip with integrated capillaries that drag examination fluids from plate wells, at the same time continuously drawing enzyme and substrates from wells integrated on chip. The mixtures are transported in a microchannel to a detection point where fluorescence readout is performed. The chips can transport a large number of examination fluids, intercalated with buffer flushing steps to

clean the system between the readings. This microfluidic network is capable of assaying with considerably higher throughput and significantly less consumption than conventional plate-based screening devices. The platform is currently used in a large number of pharmaceutical companies in HTS applications.

## 5.2 Cell-Based Devices

### 5.2.1 Simple cell-based devices

LOC technology is nowadays being increasingly investigated for developing in vitro models of different diseases/conditions or for carrying out more predictive toxicity studies. Due to the nature of biological systems, of particular interest are cell-based models, both single-cell arrays and complex 3-D cell culture systems. In in vitro models, cell type and source are the key factors influencing accurate representation of the (patho)physiological states found in vivo and thus reliability and validity of in vitro studies. To date, successful examples include primary cells of the liver, heart, and brain, among others. However, culturing of primary cells usually results in a reduction in specificity due to important alterations of the environment in cell culture vessels [94]. The current choice of microfluidic systems is owed to better mimicking the cellular microenvironment and improved cell handling, positioning, and analysis. Nevertheless, some challenges still remain, such as poor small-volume liquid handling ability, large consumption of reagents, and high cost of operation. Liu et al. [95] suggested an integration of combinatorial mixer to 3-D microfluidic device able to culture and screen the combinatorial effects of multiple-compound exposure on cultured cells. A 1 cm × 1 cm chip with a three-input combinatorial mixer and eight individually isolated microculture chambers was fabricated to proof the concept (Fig. 1.8).

Fig. 1.8 Microfluidic multiple cell culture array with an integrated combinatorial mixer. (A) Fabricated 1 cm × 1 cm chip. (B) SEM image of the cross section of the microfluidic overpass. The overpass has two-level microfluidic channels, and such structures allow that two fluidic streams are separated spatially at the overpass. (C) Surface height profile scan of the overpass region. The overpass structure is about 15–20 μm higher than the first-level microfluidic channels. Reproduced from M.C. Liu, D. Ho, Y.-C. Tai, Monolithic fabrication of three-dimensional microfluidic networks for constructing cell culture array with an integrated combinatorial mixer, *Sensors Actuators B Chem.* 129 (2008) 826–833.

Of particular importance is culturing stem cells in microfluidic platforms, since nowadays adopted cell isolation and culturing techniques are not able to predictively direct their differentiation toward relevant cell types in order to produce in vitro models of, for example, disease for drug-target evaluation or toxicity studies [96]. Microfluidic assays appear as alternatives for cell fate in vitro control by improving the spatiotemporal cell behavior, especially due to better control of biochemical and biophysical extracellular factors [97,98]. Nevertheless, the development of such platforms is still in its infancy, and more intensive focus to such investigations is necessary to propose an optimal design to control cell fate by environmental factors.

One important application of microfluidic cell culture systems is analysis of DNA damage in cancer models, an alternative to the widely accepted multistep comet electrophoresis assay, which analyzes damage and repair on a single-cell level. A microwell array patterned in an agarose layer of Wood et al. [99] not only allows single-cell trapping and high-throughput analysis of DNA damage but also overcomes impeded cell analysis because of overlapping cells. The device is fully automated and enables analysis of captured ones in microwell single cells in a single focal plane (and not overlapping). The technology is transferable to study DNA damage or drug screening in a high throughput, because the micropatterned array (microwells) can be sandwiched between a substrate and a microliter plate. Another noteworthy development is in droplet technology for drug discovery, which further elaborates encapsulation of single cells within droplets being again compatible with high-throughput screening and cell sorting [100]. For example, a droplet viability assay that allows the quantitative scoring of cell viability was developed to allow screening of drug

libraries for cytotoxic effects on cells [101]. A cell-containing droplet is combined with a fluorescently encoded one and with varied concentrations of drug, whereas the system enables their incubation during ~ 15 min before analyzing cell viability. 5.2.2 Toxicity

In case of toxicity evaluation, the information obtained from these models serves to predict the safety aspects of the potential drug candidates, where absorption, distribution, metabolism, elimination, and toxicity properties are evaluated. Accordingly, the undesirable toxicity of drug is nowadays a leading cause of drug development failures [102]. The established assays for cytotoxicity, genotoxicity, drug-drug interactions, and metabolite-mediated toxicity are microplate- and micronucleus-based ones. These evaluations are also possible to be carried out in microfluidic platforms [103–105]. Similar designs were used to go beyond the evaluation of toxicity in cells/organs, to reconstitute the metabolism of a drug, and to evaluate systemic responses in in vitro models. The provided pharmacokinetic information for early toxicity evolved into a holistic view of toxicology in vitro, to be carried out prior to more expensive in vivo investigations. One example is to evolve from cell culture analogue [106] to a microscaled “animal-on-a-chip” system that integrates cocultures of different tissues and fat cells with physiological fluid arrays on a single chip [107,108]. The chip is a model to create a surrogate predictor of animal experiments for chemical exposure assessment, something only achievable with time-consuming and costly multiple conventional toxicity studies. This chip represents a step closer to progresses that will enable robust in vitro toxicology models for testing pharmacokinetic profiles of drugs and systemic toxicity specific to humans, instead of animals [109]. Of course, for the viable adoption in pharma, both high-throughput and high-content assays must be conductible, which means properly designed and integrated microfluidic setup. Additionally, research and development efforts should also be directed to microfluidic systems for functional 3-D cell cultures. 5.2.3

### Three-dimensional cell culture

Growing cells in 3-D brings about several advantages to flat-layer culturing: (i) altered cell morphology, (ii) more realistic drug response due to increased resistance, (iii) captured phenotypic heterogeneity, and (iv) mimic of the tumor environment. Also, in addition to controversies related to in vivo testing, many cancers still lack qualified animal models. Compared with flat cell layers, 3-D cultured cells more closely resemble cell-cell interactions and tumor heterogeneities in vivo [110]. On the minus side, 3-D cell elaboration is more complicated and costly than already adopted and reasonably reliable monolayer cultures. Nevertheless, new developments in chip technologies and microfluidic platforms are now paving the way for more feasible and affordable 3-D cell cultures and experiments.

For example, micropatterned substrates can be used to precisely control the size and shape of the multicellular aggregates (microtissues), which enable the optimal supply of nutrients to cells and the removal of undesired metabolites. In this context, the fabrication of temperature-responsive microarrays for the formation of artificial tissue of controlled size and shape as tissue models for drug discovery is particularly interesting [111]. Thus, temperature-responsive poly(N-isopropylacrylamide) polymer micropatterns provide reversible states of cell-adherent (37°C) and cell-repellent (24°C) behavior. Alternatively, microtissues can be processed in microfluidic devices via photo encapsulation of up to 1000 cells in polyethylene glycol hydrogels, so that the microtissues could be studied with a multiplexed microfluidic approach [112]. The mechanically stabilized microtissues of 250–350 µm have been used in high-throughput flow sorting and analysis, as an example of quantitative statistical analysis. On the other hand, strategies using continuous-flow lithographic encoding can be used in similar methods as an attempt to improve multiplexing capabilities [113]. Such attempts are directed to the standardization of high-throughput tests to evaluate the response of 3-D models to different drugs and their combinations. In light with the aforementioned, new microfluidic platforms provided with increased functionality are developed to improve data quality from in vitro assays [114,115]. However, besides providing deeper insight into the spatiotemporal cues that govern cell fates, the

key point is to turn these platforms into high-throughput devices with sufficient accuracy for drug discovery platforms. Chi et al. excellently reviewed how the scientific advances turned out into more matured 3-D biomicrofabrication technologies and exemplified several companies offering chips for reliable biochemical assays; cell/biomarker and infectious disease diagnostics; and 3-D models for drug discovery, screening, and delivery [37].

5.3

Organs-On-A-Chip, A Step Toward Whole Body Models

### 5.3.1 Organs-on-a-chip

Going beyond cell-cell interactions in 3-D chip models, efforts are being carried out to optimize the fabrication of microfluidic devices that combine several cell types in 2-D or 3-D designs in order to simulate human organs on a single chip [116,117]. Such chips resemble more closely complex interactions between different tissues and organs, in contrast to mimicking interactions between cells of the same type in 3-D models [34]. Thus, these systems hold enormous potential to reduce or even completely replace animal testing because they circumvent the major limitation of in vivo tests, that is, metabolic differences between humans and animals. It is expected that the obtained information on drug efficacy and toxicity on an organ level will allow more accurate early-phase decisions in future drug development.

From a technological point of view and in order to successfully simulate tissue-tissue interactions, a model with different cell types cultured in 3-D designs but using separate chambers is proposed, where the microtissues were connected by a microfluidic network [118]. The connective network allows for reproduction of the pharmacokinetic profiles of drugs simultaneously in cancerous and healthy tissues, which were by far different to the effects observed in a conventional microplate assay. It is worth mentioning that additional experimentation should be made for adjusting tissue geometries and channel profiles so that fluid residence times correspond to physiological residence times of body fluids in the targeted organs. In a similar approach, a compartmental design has been proved to be successful for the fabrication of a bilayer silicon microfluidic structure, aimed to mimic alveolar-capillary interface of a human lung while integrating mechanical cell actuation [119]. The mechanical actuation was simulated by applying vacuum at the separate ends of a middle channel with cultured human alveolar epithelial cells in the air on the upper side, whereas the lower channel contained a fluid with vascular endothelial cells. The resulting stretching of the silicone membrane enhanced cellular uptake of nanoparticles, influencing inflammatory responses similarly as in in vivo studies. In a more complex approach, the reconstitution of a small artery on a microfluidic chip was achieved by Gunther et al. [120]. A triple microchannel system for the fixation, perfusion, and superfusion of the vessel was used for long-term culture and investigation under the influence of phenylephrine or acetylcholine. This system may thus present a ground-breaking achievement for enabling pharmacological and toxicological screens and evaluate the effect of new drugs in the arteries. Readers are further encouraged to search the references from Table 1.1, containing some of the most relevant examples of organs-on-a-chip.

Table 1.1

Examples for organs-on-a-chip for drug testing and delivery

Besides toxicological response in 3-D model platforms that comprised healthy cells to mimic human organs, modeling microfluidic platforms that resemble in vivo cancerous situations is of especial interest for pharmacological monitoring of drug effects. The so-called tumors-on-a-chip are models aimed to screen the behavior of cancer cells, for example, anti-angiogenesis, during the treatment with drugs; investigate interaction between healthy and tumor cells; or focus on improving the detection of cancer at the disease onset. For the latter, microfluidic devices are designed with lateral channel structures in which circulating tumor cells or relevant biomarkers in

small concentrations are collected and quantified [133,134]. More complex structures are necessary to be developed for detailed recapitulation of tumor microenvironments, such as recently developed in vitro model with 3-D structure of microfluidic channels where tumor cells and endothelial cells are cultured within extracellular matrix under perfusion of interstitial fluid [135]. The system allows simulation of complex drug transport around the tumor and is tested with nanoparticulate-based therapeutic agents aiming at targeted delivery of therapy. The information obtained from this tumor-microenvironment-on-chip model is particularly relevant as it provides guidance for design of nanoparticles (including perception about optimal size and morphology) in the associated therapeutic approaches.

Although the principles for developing tumor models or hybrid tumor models (comprising both tumor and healthy cells) are similar for different cancer types, only individual investigations on each particular model can give specifics regarding the effectiveness of therapeutic approaches, regardless of their nature. Thus, it is of paramount importance that the microenvironments of specific tumors are matched in those models. Studies are continuously reported, while here, we highlight the progresses in the development of lung [136,137], breast [138], prostate [139,140], pancreas [141], and brain [142] cancer models, for various purposes in cancer research.

### 5.3.2 Multiple organs-on-a-chip

A further step not only toward ultimate realistic investigation models but also toward complexity is culturing multiple organs-on-a-chip (Fig. 1.9) [144–146]. Particularly challenging for providing reliability in these authentic whole-body-on-a-chip systems is the necessary allometric scaling effect of the microorgans. Thus, scaling must involve mass allometrics of the organs, coupled to mimicking different blood circulation and pulse through the organs. In addition, the preservation of the important organ functions is paramount during scaling, all connected to raising challenges of the microfluidic design. Finally, interconnecting of organs-on-a-chip should follow the real interaction of organs in humans, that is, which organs must interact with others and which must not come into contact with the common medium. The common medium must be “friendly” for all cells in the model.

Fig. 1.9 The human-on-a-chip concept. Biomimetic microsystems representing different organs can be integrated into a single microdevice and linked by a microfluidic circulatory system in a physiologically relevant manner to model a complex, dynamic process of drug absorption, distribution, metabolism, and excretion and to more reliably evaluate drug efficacy and toxicity. As shown in this example, an integrated system of microengineered organ mimics (the lung, heart, gut, liver, kidney, and bone) can be used to study the absorption of inhaled aerosol drugs (“aerosol drug”) from the lung to microcirculation and to measure their cardiotoxicity (e.g., changes in heart contractility or conduction), transport and clearance in the kidney, metabolism in the liver, and immune-cell contributions to these responses. Drug substances (“oral drug”) also can be introduced into the gut compartment to investigate interplay between orally administered drugs and molecular transporters and metabolizing enzymes expressed in the various organs [143].

As a standout work on a multichannel 3-D system, integrating microorgans of liver, lung, kidney, and fat tissue was presented by Zhang et al. [147]. A common medium was maintaining the functions of four different cell lines (i.e., microorgans), coming from one reservoir with connections to an inlet directly attached to each cell group. Such design enables testing the multi-organ implications in drug delivery and toxicity. In an ideal scenario (without a drug), all cells were able to function above 90% of their usual activity. When tested with a growth factor, growth was promoted in three out of four cell lines, with a significantly lower viability of the fourth line. In a further experiment involving protein microspheres to control the growth factor release into only one cell line group, the results showed that it is possible to selectively stimulate one particular cell line without adverse effects to other cells.

Another multiple organs-on-a-chip was designed to test drug toxicity in three different cell lines separated in three culture chambers, which enabled mapping drug pharmacological effects [148]. The device was tested with healthy liver cells, colon tumor cells, and leukemic cells. A reservoir containing suitable medium was connected to the three cell culture chambers, whereas the medium flow rate was controlled by gravity. An anticancer drug was used for testing, showing a decline in viability between all three cell groups.

Besides culturing tissues and multiple organs, microfluidic devices are increasingly investigated for improved screening and data synthesis of animal organisms. Small vertebrates are very useful in drug discovery for testing on a systemic level; however, with conventional methods, the testing is usually highly complex, dependent on many low controllable factors, and time-consuming. Automated microscopy [149] and especially microfluidics are significantly simplifying and accelerating the testing. Microfluidic platforms simplify the handling, positioning, orienting, and manipulating of the entire organisms and analyses, proved on different organisms, such as not parasitic worms [150], embryos of a fly [151,152], or zebra fish [153]. Exemplified, microfluidic arrays are able to order and vertically orient, for example, fly embryos on a large scale to enable quantitative imaging of the embryos in a position not possible with traditional coverslip-based approaches. A microscale meandering manifold injects and transports the embryos to intersections with cross-flow channels where the similar in size embryos are vertically trapped in a cylindrical cutout controlled by the injection pressure. Then, the embryos can be securely transported in the orientation essential for high-throughput screening systems, for example, to allow quantitative analysis of different patterns within the biosystem [151]. The model was also successfully translated to high-throughput assays and monitoring developmental responses of embryos to external stimuli [154]. Another example is a high-throughput system for automated investigations, proved for chemical and genetic screening of zebra fish larvae [153]. All the steps of the system were automated, from loading the larvae, optical detection, positioning and rotation in a rotatable capillary, image focusing and acquisition, laser manipulation, and dispensing step back into a multiwell plate. The system is able to provide confocal imaging and laser-based microsurgery of oriented zebra fish larvae within less than 20 s and set the basis for similar investigations [155,156].

## 6 Summary and Outlook

An overview of the main topics related to microfluidics for pharmaceutical applications has been provided demonstrating the technological ability to miniaturize many larger-scale complex processes and giving rise to the LOC concept.

With respect to pharmaceutical applications, microfluidic systems, together with the inherent advantages of miniaturization, low cost, fast processing, and low sample quantity, allow to obtain high-quality, high-throughput data, which is particularly relevant for drug development and testing. Microfluidics-based drug testing platforms allow evaluating time-dependent dynamics, toxicity, and multicell interactions. Thus, performance and eventual side effects of drugs not only are detected but also allow evaluating the underlying mechanisms of drug response. Particularly interesting is the mimicking of the in vivo microenvironments and the organ-on-a-chip approach that will, eventually, lead to realistically mimic characteristics and functionality of a whole-body response. This will represent a major breakthrough not only in the pharmaceutical area but also in the whole biomedical field.

Finally, it has been shown that the major future trends and needs in this field are the development of high-performance microscale research and development platforms and the fabrication of low-cost, portable analysis systems. In this context, a strong interdisciplinary approach is needed, ranging from the essential knowledge of the physical-chemical aspect of materials and processes to the development of suitable materials and production technologies, taking into account the biomedical aspects of the final application. All these together will allow overcoming the present limitations and needs of these microtechnologies with huge macro implications.

## References

- [1] Terry S.C., Jerman J.H., Angell J.B. Gas-chromatographic air analyzer fabricated on a silicon-wafer. *IEEE Trans. Electr. Dev.* 1979;26:1880–1886.
- [2] Manz A., Graber N., Widmer H.M. Miniaturized total chemical analysis systems: a novel concept for chemical sensing. *Sensors Actuators B Chem.* 1990;1:244–248.
- [3] Rios A., Zougagh M., Avila M. Miniaturization through lab-on-a-chip: utopia or reality for routine laboratories? A review. *Anal. Chim. Acta.* 2012;740:1–11.
- [4] Maguire T.J., Novik E., Chao P., Barminko J., Nahmias Y., Yarmush M.L., Cheng K.C. Design and application of microfluidic systems for in vitro pharmacokinetic evaluation of drug candidates. *Curr. Drug Metab.* 2009;10:1192–1199.
- [5] Chin C.D., Linder V., Sia S.K. Commercialization of microfluidic point-of-care diagnostic devices. *Lab Chip.* 2012;12:2118–2134.
- [6] Chao T.-C., Hansmeier N. Microfluidic devices for high-throughput proteome analyses. *Proteomics.* 2013;13:467–479.
- [7] Inamdar N.K., Borenstein J.T. Microfluidic cell culture models for tissue engineering. *Curr. Opin. Biotechnol.* 2011;22:681–689.
- [8] Skardal A., Shupe T., Atala A. Organoid-on-a-chip and body-on-a-chip systems for drug screening and disease modeling. *Drug Discov. Today.* 2016;21:1399–1411.
- [9] Li H.F., Lin J.M. Applications of microfluidic systems in environmental analysis. *Anal. Bioanal. Chem.* 2009;393:555–567.
- [10] Chin C.D., Linder V., Sia S.K. Lab-on-a-chip devices for global health: past studies and future opportunities. *Lab Chip.* 2007;7:41–57.
- [11] Sackmann E.K., Fulton A.L., Beebe D.J. The present and future role of microfluidics in biomedical research. *Nature.* 2014;507:181–189.
- [12] Mark D., Haeberle S., Roth G., Von Stetten F., Zengerle R. Microfluidic lab-on-a-chip platforms: requirements, characteristics and applications. *Chem. Soc. Rev.* 2010;39:1153–1182.
- [13] FluidicMEMS. *List of microfluidics companies (online)*. Available from: <http://fluidicmems.com/list-of-microfluidics-lab-on-a-chip-and-biomems-companies/>. 2016 (accessed February 2017).
- [14] Weigl B.H., Bardell R.L., Cabrera C.R. Lab-on-a-chip for drug development. *Adv. Drug Deliv. Rev.* 2003;55:349–377.
- [15] Bjornmalm M., Yan Y., Caruso F. Engineering and evaluating drug delivery particles in microfluidic devices. *J. Control. Release.* 2014;190:139–149.
- [16] Dittrich P.S., Manz A. Lab-on-a-chip: microfluidics in drug discovery. *Nat. Rev. Drug Discov.* 2006;5:210–218.
- [17] Pihl J., Karlsson M., Chiu D.T. Microfluidic technologies in drug discovery. *Drug Discov. Today.*

2005;10:1377–1383.

[18] Lenshof A., Laurell T. Continuous separation of cells and particles in microfluidic systems. *Chem. Soc. Rev.* 2010;39:1203–1217.

[19] Pamme N. Continuous flow separations in microfluidic devices. *Lab Chip.* 2007;7:1644–1659.  
\*

---

*Microfluidics for Pharmaceutical Applications: From Nano/Micro Systems Fabrication to Controlled Drug Delivery* is a concept-orientated reference that features case studies on utilizing microfluidics for drug delivery applications. It is a valuable learning reference on microfluidics for drug delivery applications and assists practitioners developing novel drug delivery platforms using microfluidics. It explores advances in microfluidics for drug delivery applications from different perspectives, covering device fabrication, fluid dynamics, cutting-edge microfluidic technology in the global drug delivery industry, lab-on-chip nano/micro fabrication and drug encapsulation, cell encapsulation and delivery, and cell- drug interaction screening.

These microfluidic platforms have revolutionized the drug delivery field, but also show great potential for industrial applications. Presents detailed coverage on the fabrication of novel drug delivery systems with desired characteristics, such as uniform size, Janus particles, and particular or combined responsiveness. Includes a variety of case studies that explain principles. Focuses on commercialization, cost, safety, society and educational issues of microfluidic applications, showing how microfluidics is used in the real world

---

Journal Rankings on Nanoscience and Nanotechnology - The microspheres' thermal properties showed their suitability for magnetic hyperthermia of First, the optical path of the nanojet across the PV layer for the oblique They restrict the flow across the pipes and ensure leakage proof system.. number of applications of great importance for science, technology and medicine. Technical Program Digest - IEEE NEMS - Purchase *Microfluidics for Pharmaceutical Applications* - 1st Edition. Print Book & E-Book. From *Nano/Micro Systems Fabrication to Controlled Drug Delivery*. 0.0 star rating View all volumes in this series: *Micro and Nano Technologies*. Biosensor Ppt - "Pharmaceutical Research ". medical problems with applications in tissue engineering, prosthetics, drug delivery, biosensors, and medical devices. heart valves, ligaments, microvascular networks, skeletal muscle, and skin - bone of *Pharmaceutical Controlled Release Technology, Photonic Polymer Systems, and Biopolymer Journal* - *Microfluidics for Pharmaceutical Applications: From Nano/Micro Systems Fabrication to Controlled Drug Delivery* is a concept-orientated reference

that features... ID: 4482947; Book; October 2018; 495 Pages; Elsevier Science and Technology cutting-edge microfluidic technology in the global drug delivery industry, 43 Best Pharmaceutical Books of All Time - BookAuthority - Microfluidics for Pharmaceutical Applications: From Nano/Micro Sy. Category Other; Type E-Books; Language English; Total size 52.1 MB; Uploaded By bookflare From Nano/Micro Systems Fabrication to Controlled Drug Delivery is a fabrication, fluid dynamics, cutting-edge microfluidic technology in Nanotechnologies for biomedical science and translational - Book Chapter, Microfluidics for Pharmaceutical Applications: From Nano/Micro Systems Fabrication to Controlled Drug Delivery, Helder Santos, Dongfei Book Chapter, Transactions on Engineering Technologies, Sio-long Ao, Len Gelman, MTB Europe Nanotechnology news - Potential medical applications for small pumps include controlled delivery and monitoring of minute amount of medication, manufacturing of nanoliters of chemicals, and Global funding for micro- and nanotechnology research and development Journal of Microelectromechanical Systems, Journal of Micromechanics and Nanotechnology Companies, Research and Degree - Microfluidics for Pharmaceutical Applications: From Nano/Micro Sy. Category Other; Type E-Books; Language English; Total size 52.1 MB; Uploaded By bookflare From Nano/Micro Systems Fabrication to Controlled Drug Delivery is a fabrication, fluid dynamics, cutting-edge microfluidic technology in Publications - Zhang Laboratory - Biolab provide Swimming pool chemical dosing systems and swimming pool Biolab is applications. has been a world leader in the production and supply of range of affordable tests of micronutrient status. uk La Jolla, CA, <http://lajollalibrary>. analysis systems using nanopore technology University of Hertfordshire. Liposomal machine - Dizzm - European Drug Delivery & Formulation Summit: The sessions dedicated on the nanomedicine, peptide, gene and protein delivery, pharmaceutical devices and on the technology and systems in the sensors, actuators, microsystems and and collaborative ties between leading international micro and nano- fluidics recommended books process of drug - Nano2Clinic - Abstract. Microfluidics for Pharmaceutical Applications: From Nano/Micro Systems Fabrication to Controlled Drug Delivery is a concept-orientated reference that features case studies on utilizing microfluidics for drug delivery applications.

---

## Relevant Books

---

[ [DOWNLOAD](#) ] - Ebook My Life is My Creation: How the Law of Attraction is Changing My World Vol. 1, July 2013 - May 2014 pdf

---

**[ DOWNLOAD ]** - Download book The Other Side of Me (All the Things Book 4) online

---

**[ DOWNLOAD ]** - Online Like Mother Like Daughter (Katy Bowman Book 1) epub, pdf

---

**[ DOWNLOAD ]** - Download book The Cambridge Modern History Collection free epub, pdf online

---

**[ DOWNLOAD ]** - Best Synthetic Methods: Acetylenes, Allenes and Cumulenes (Best Synthetic Methods) free online

---